Drug profile · INN
tepotinib hydrochloride
TEPMETKO
tepotinib hydrochloride (TEPMETKO) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tepotinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
tepotinib hydrochloride (TEPMETKO) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: Hepatocyte growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tepotinib hydrochloride?
tepotinib hydrochloride (TEPMETKO) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tepotinib hydrochloride?
TEPMETKO is a marketed brand name for tepotinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tepotinib hydrochloride?
tepotinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.